Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky

Abema and Ribo - Adjuvant High Risk EBC with Dr. Aalok Kumar

In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.

Targeted therapy in Cholangiocarcinoma - Part 2 - Ivosidenib

In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib (PART 1) to target FGFR2 fusions and Ivosidenib (PART 2) for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.

Targeted therapy in Cholangiocarcinoma - Part 1 - Pemigatinib

In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib to target FGFR2 fusions and Ivosidenib for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.

You Are What You Eat - Diet and Cancer with Dr. Urvi Shah

In this episode, Dr. Urvi Shah takes us through how to optimize diet in cancer treatment and prevention.

Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky

In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib.